Dallas Ebola patient waited nearly a week for experimental drug; family claims bias

Duncan given alternative Ebola treatment
Duncan given alternative Ebola treatment

    JUST WATCHED

    Duncan given alternative Ebola treatment

MUST WATCH

Duncan given alternative Ebola treatment 04:51

Story highlights

  • FDA says it received the request for the treatment on October 3
  • Thomas Eric Duncan was admitted for Ebola on September 28
  • Duncan died Wednesday, the hospital said
  • Hospital: Duncan was "treated the way any other patient would have been treated"
Thomas Eric Duncan, the first person diagnosed with Ebola in the United States, received an experimental medicine nearly a week after being admitted into the hospital -- a far longer wait than experienced by four other Ebola patients treated in the United States.
Those patients -- two each at Atlanta's Emory University Hospital and the University of Nebraska Medical Center -- received their experimental medicines immediately. Those four are U.S. citizens; Duncan is a Liberian national.
Duncan died Wednesday at the Texas hospital where he was being treated, 10 days after he was admitted.
"We feel he didn't get the medicine and treatment for the disease because he's African and they don't consider him as important as the other three," Josephus Weeks, Duncan's nephew, said at a press conference Tuesday afternoon, a day before Duncan died.
The Rev. Jesse Jackson, who attended that press conference with Weeks and Duncan's mother as a newly appointed spokesman for the family, said, "We don't feel good about that. It's been a concern he had to wait so long."
Could ZMapp be the cure for Ebola?
Could ZMapp be the cure for Ebola?

    JUST WATCHED

    Could ZMapp be the cure for Ebola?

MUST WATCH

Could ZMapp be the cure for Ebola? 02:49
Pastor: Family devastated by Ebola death
Pastor: Family devastated by Ebola death

    JUST WATCHED

    Pastor: Family devastated by Ebola death

MUST WATCH

Pastor: Family devastated by Ebola death 02:50
Partner of victim: 'His suffering is over'
Partner of victim: 'His suffering is over'

    JUST WATCHED

    Partner of victim: 'His suffering is over'

MUST WATCH

Partner of victim: 'His suffering is over' 01:26
With Ebola vaccine, ethical questions
With Ebola vaccine, ethical questions

    JUST WATCHED

    With Ebola vaccine, ethical questions

MUST WATCH

With Ebola vaccine, ethical questions 02:07
Jackson said he thinks money also played a role in Duncan's treatment.
"I would tend to think that those who do not have insurance, those who do not have Medicaid do not have the same priorities as those who do," the civil rights leader said.
In a statement, a spokeswoman for Dallas' Texas Health Presbyterian Hospital said Duncan was "treated the way any other patient would have been treated, regardless of nationality or ability to pay for care. We have a long history of treating a multicultural community in this area."
The hospitals that took care of the four other patients had substantial advance notice that patients were on their way.
Duncan went the emergency room at Texas Health Presbyterian Hospital on September 25, but staff there didn't realize he had Ebola and sent him home hours later. He was admitted on September 28 when the hospital realized he had the disease. He started receiving the experimental drug, brincidofovir, on October 4.
"Mr. Duncan succumbed to an insidious disease, Ebola," hospital spokesman Wendell Watson said in a statement. "He fought courageously in this battle. Our professionals, the doctors and nurses in the unit, as well as the entire Texas Health Presbyterian Hospital Dallas community, are also grieving his passing."
Since the drugs being used to treat Ebola are still experimental, it is up to each individual hospital to file the paperwork with the Food and Drug Administration for permission to get the drug from the manufacturer and use it.
The agency received the request to use brincidofovir on October 3, five days after Duncan entered the hospital, Stephanie Yao, a spokeswoman for the FDA, said Wednesday.
"The care team has been consulting with the CDC and Emory, on a daily basis since Mr. Duncan was admitted to the hospital, discussing the possible course of treatment, including the use of investigational drugs," Watson, the hospital spokesman, said in a statement.
The FDA and Chimerix, the company that makes the drug, said if there was any delay it wasn't on their part. Yao said she couldn't comment on any particular case, but when doctors make requests for experimental Ebola treatments, "we turn them around in a matter of a few hours -- often less than one hour."
Joseph Schepers, a spokesman for Chimerix, said requests to use brincidofovir "are expedited immediately in the most expedited way you could possibly do it."
"It's a general rule in medicine that the earlier you start therapy in a sick person who needs the therapy, the better the response," said Dr. Anthony Fauci, director of the National Institute for Allergies and Infectious Diseases, when asked about the impact of the wait for the drug.
Weeks said he and his family had to "pressure" the hospital to apply for permission to give the drug, brincidofovir, to Duncan.
"They were treating him with oxygen, water and a bed to lay on," he said.
Weeks and Jackson said they believe the hospital applied for permission to use brincidofovir only after Jackson gave out the hospital's phone number on his radio show last week and urged listeners to call in and complain.
Ashoka Mukpo, a freelance NBC cameraman, was admitted to the University of Nebraska Medical Center Tuesday and began receiving brincidofovir the same day. Dr. Rick Sacra received another experimental drug called TKM-Ebola, which is easier to access but still requires permission from the FDA. Dr. Kent Brantley and Nancy Writebol -- both treated at Emory -- took Zmapp, which is no longer available because the company ran out of supplies of the drug.